A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

@JackWestMD @PatelOncology @FordePatrick @n8pennell @drgandara The median OS was 7.something months for both treatment arms, and the primary endpoint of OS was not met despite slightly better ORR and PFS for the experimental arm. It was the JUNIPER trial o

New research: A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER: Introduction JUNIPER compared the… https://t.c